333 related articles for article (PubMed ID: 28986235)
1. Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy for management.
Phillipson OT
Ageing Res Rev; 2017 Nov; 40():149-167. PubMed ID: 28986235
[TBL] [Abstract][Full Text] [Related]
2. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
3. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.
Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450
[TBL] [Abstract][Full Text] [Related]
4. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
5. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
[TBL] [Abstract][Full Text] [Related]
6. Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease.
Naoi M; Maruyama W; Shamoto-Nagai M; Riederer P
J Neural Transm (Vienna); 2024 Jun; 131(6):639-661. PubMed ID: 38196001
[TBL] [Abstract][Full Text] [Related]
7. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.
Burbulla LF; Song P; Mazzulli JR; Zampese E; Wong YC; Jeon S; Santos DP; Blanz J; Obermaier CD; Strojny C; Savas JN; Kiskinis E; Zhuang X; Krüger R; Surmeier DJ; Krainc D
Science; 2017 Sep; 357(6357):1255-1261. PubMed ID: 28882997
[TBL] [Abstract][Full Text] [Related]
8. Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease.
Sohrabi T; Mirzaei-Behbahani B; Zadali R; Pirhaghi M; Morozova-Roche LA; Meratan AA
J Mol Biol; 2023 Jun; 435(12):167992. PubMed ID: 36736886
[TBL] [Abstract][Full Text] [Related]
9. Management of the aging risk factor for Parkinson's disease.
Phillipson OT
Neurobiol Aging; 2014 Apr; 35(4):847-57. PubMed ID: 24246717
[TBL] [Abstract][Full Text] [Related]
10. Determinants of dopaminergic neuron loss in Parkinson's disease.
Surmeier DJ
FEBS J; 2018 Oct; 285(19):3657-3668. PubMed ID: 30028088
[TBL] [Abstract][Full Text] [Related]
11. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
12. Drp-1 dependent mitochondrial fragmentation and protective autophagy in dopaminergic SH-SY5Y cells overexpressing alpha-synuclein.
Martinez JH; Alaimo A; Gorojod RM; Porte Alcon S; Fuentes F; Coluccio Leskow F; Kotler ML
Mol Cell Neurosci; 2018 Apr; 88():107-117. PubMed ID: 29414102
[TBL] [Abstract][Full Text] [Related]
13. Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease.
Bobela W; Aebischer P; Schneider BL
Biomolecules; 2015 Oct; 5(4):2675-700. PubMed ID: 26501339
[TBL] [Abstract][Full Text] [Related]
14. Motor deficits and beta oscillations are dissociable in an alpha-synuclein model of Parkinson's disease.
Brys I; Nunes J; Fuentes R
Eur J Neurosci; 2017 Aug; 46(3):1906-1917. PubMed ID: 28370471
[TBL] [Abstract][Full Text] [Related]
15. Impairment of Macroautophagy in Dopamine Neurons Has Opposing Effects on Parkinsonian Pathology and Behavior.
Hunn BHM; Vingill S; Threlfell S; Alegre-Abarrategui J; Magdelyns M; Deltheil T; Bengoa-Vergniory N; Oliver PL; Cioroch M; Doig NM; Bannerman DM; Cragg SJ; Wade-Martins R
Cell Rep; 2019 Oct; 29(4):920-931.e7. PubMed ID: 31644913
[TBL] [Abstract][Full Text] [Related]
16. Parkinson disease: from pathology to molecular disease mechanisms.
Dexter DT; Jenner P
Free Radic Biol Med; 2013 Sep; 62():132-144. PubMed ID: 23380027
[TBL] [Abstract][Full Text] [Related]
17. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
18. PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein.
Ciron C; Zheng L; Bobela W; Knott GW; Leone TC; Kelly DP; Schneider BL
Acta Neuropathol Commun; 2015 Apr; 3():16. PubMed ID: 25853296
[TBL] [Abstract][Full Text] [Related]
19. Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders.
Wise RM; Wagener A; Fietzek UM; Klopstock T; Mosharov EV; Zucca FA; Sulzer D; Zecca L; Burbulla LF
Neurobiol Dis; 2022 Dec; 175():105920. PubMed ID: 36351559
[TBL] [Abstract][Full Text] [Related]
20. Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein.
Brito-Armas JM; Baekelandt V; Castro-Hernández JR; González-Hernández T; Rodríguez M; Castro R
Histol Histopathol; 2013 Aug; 28(8):999-1006. PubMed ID: 23444197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
